These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ibrutinib dose modifications in the management of CLL. Hardy-Abeloos C; Pinotti R; Gabrilove J J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582 [TBL] [Abstract][Full Text] [Related]
4. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536 [TBL] [Abstract][Full Text] [Related]
5. Managing toxicities of Bruton tyrosine kinase inhibitors. Lipsky A; Lamanna N Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):336-345. PubMed ID: 33275698 [TBL] [Abstract][Full Text] [Related]
6. Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations. Carda JP; Santos L; Mariz JM; Monteiro P; Gonçalves HM; Raposo J; Gomes da Silva M Hematology; 2021 Dec; 26(1):785-798. PubMed ID: 34605364 [TBL] [Abstract][Full Text] [Related]
7. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. de Weerdt I; Koopmans SM; Kater AP; van Gelder M Haematologica; 2017 Oct; 102(10):1629-1639. PubMed ID: 28775119 [TBL] [Abstract][Full Text] [Related]
8. Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical. Dong R; Yan Y; Zeng X; Lin N; Tan B Drug Des Devel Ther; 2022; 16():3225-3239. PubMed ID: 36164415 [TBL] [Abstract][Full Text] [Related]
9. Haemorrhagic bullae and purpura associated with the Bruton tyrosine kinase inhibitor ibrutinib. Steele L; George C; Cerio R; O'Toole EA Clin Exp Dermatol; 2022 Feb; 47(2):488-490. PubMed ID: 34882824 [No Abstract] [Full Text] [Related]
10. Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections. Maffei R; Maccaferri M; Arletti L; Fiorcari S; Benatti S; Potenza L; Luppi M; Marasca R Blood Rev; 2020 Mar; 40():100635. PubMed ID: 31699465 [TBL] [Abstract][Full Text] [Related]
11. Management of adverse effects/toxicity of ibrutinib. Paydas S Crit Rev Oncol Hematol; 2019 Apr; 136():56-63. PubMed ID: 30878129 [TBL] [Abstract][Full Text] [Related]
12. Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib. Lasica M; Tam CS Hematol Oncol Clin North Am; 2021 Aug; 35(4):761-773. PubMed ID: 34174985 [TBL] [Abstract][Full Text] [Related]
13. The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia. Gianfelici V; Levato L; Molica S Curr Hematol Malig Rep; 2020 Aug; 15(4):343-349. PubMed ID: 32500413 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies. Lama TG; Kyung D; O'Brien S Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127 [TBL] [Abstract][Full Text] [Related]
15. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre. Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654 [TBL] [Abstract][Full Text] [Related]
16. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Tang CPS; McMullen J; Tam C Leuk Lymphoma; 2018 Jul; 59(7):1554-1564. PubMed ID: 28901789 [TBL] [Abstract][Full Text] [Related]
17. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation. Sestier M; Hillis C; Fraser G; Leong D Curr Oncol Rep; 2021 Aug; 23(10):113. PubMed ID: 34342738 [TBL] [Abstract][Full Text] [Related]